The global burden of liver disease: the major impact of China
- PMID: 25164003
- PMCID: PMC4867229
- DOI: 10.1002/hep.27406
The global burden of liver disease: the major impact of China
Abstract
Liver disease is a major cause of illness and death worldwide. In China alone, liver diseases, primarily viral hepatitis (predominantly hepatitis B virus [HBV]), nonalcoholic fatty liver disease, and alcoholic liver disease, affect approximately 300 million people. The establishment of the Expanded Program on Immunization in 1992 has resulted in a substantial decline in the number of newly HBV-infected patients; however, the number of patients with alcoholic and nonalcoholic fatty liver diseases is rising at an alarming rate. Liver cancer, one of the most deadly cancers, is the second-most common cancer in China. Approximately 383,000 people die from liver cancer every year in China, which accounts for 51% of the deaths from liver cancer worldwide. Over the past 10 years, China has made some significant efforts to shed its "leader in liver diseases" title by investing large amounts of money in funding research, vaccines, and drug development for liver diseases and by recruiting many Western-trained hepatologists and scientists. Over the last two decades, hepatologists and scientists in China have made significant improvements in liver disease prevention, diagnosis, management, and therapy. They have been very active in liver disease research, as shown by the dramatic increase in the number of publications in Hepatology. Nevertheless, many challenges remain that must be tackled collaboratively. In this review, we discuss the epidemiology and characteristics of liver diseases and liver-related research in China.
© 2014 by the American Association for the Study of Liver Diseases.
Figures
Comment in
-
Reply: To PMID 25164003.Hepatology. 2015 Nov;62(5):1640-1. doi: 10.1002/hep.27768. Epub 2015 Apr 8. Hepatology. 2015. PMID: 25722010 No abstract available.
-
Liver disease in China: A long way to go.Hepatology. 2015 Nov;62(5):1640. doi: 10.1002/hep.27769. Epub 2015 Mar 25. Hepatology. 2015. PMID: 25722082 No abstract available.
-
Reply.Hepatology. 2016 Jan;63(1):348. doi: 10.1002/hep.27879. Epub 2015 Jun 19. Hepatology. 2016. PMID: 25953045 No abstract available.
-
Contribution of nonignorable environmental factor to impairing liver disease mortality reduction target in China.Hepatology. 2016 Jan;63(1):347-8. doi: 10.1002/hep.27882. Epub 2015 Jun 19. Hepatology. 2016. PMID: 25953408 No abstract available.
Similar articles
-
Global liver disease burdens and research trends: Analysis from a Chinese perspective.J Hepatol. 2019 Jul;71(1):212-221. doi: 10.1016/j.jhep.2019.03.004. Epub 2019 Mar 12. J Hepatol. 2019. PMID: 30871980 Review.
-
China's efforts to shed its title of "Leader in liver disease".Drug Discov Ther. 2007 Oct;1(2):84-5. Drug Discov Ther. 2007. PMID: 22504391
-
The inception, achievements, and implications of the China GAVI Alliance Project on Hepatitis B Immunization.Vaccine. 2013 Dec 27;31 Suppl 9:J15-20. doi: 10.1016/j.vaccine.2013.03.045. Vaccine. 2013. PMID: 24331015 Review.
-
Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & Hepatology Commission.Lancet Gastroenterol Hepatol. 2020 Feb;5(2):167-228. doi: 10.1016/S2468-1253(19)30342-5. Epub 2019 Dec 15. Lancet Gastroenterol Hepatol. 2020. PMID: 31852635 Free PMC article. Review.
-
Hepatology after Hepatitis C.Dig Dis. 2016;34(5):603-6. doi: 10.1159/000445276. Epub 2016 Jun 22. Dig Dis. 2016. PMID: 27332966
Cited by
-
Evaluation of high-risk factors and the diagnostic value of alpha-fetoprotein in the stratification of primary liver cancer.World J Clin Cases. 2022 Sep 16;10(26):9264-9275. doi: 10.12998/wjcc.v10.i26.9264. World J Clin Cases. 2022. PMID: 36159417 Free PMC article.
-
FibroBox: a novel noninvasive tool for predicting significant liver fibrosis and cirrhosis in HBV infected patients.Biomark Res. 2020 Sep 25;8:48. doi: 10.1186/s40364-020-00215-2. eCollection 2020. Biomark Res. 2020. PMID: 33005419 Free PMC article.
-
Hydrogen gas alleviates acute alcohol-induced liver injury by inhibiting JNK activation.Exp Ther Med. 2021 May;21(5):453. doi: 10.3892/etm.2021.9884. Epub 2021 Mar 1. Exp Ther Med. 2021. PMID: 33767761 Free PMC article.
-
The Decade-Long Chinese Methadone Maintenance Therapy Yields Large Population and Economic Benefits for Drug Users in Reducing Harm, HIV and HCV Disease Burden.Front Public Health. 2019 Nov 12;7:327. doi: 10.3389/fpubh.2019.00327. eCollection 2019. Front Public Health. 2019. PMID: 31781529 Free PMC article.
-
Single-Ascending-Dose, Food-Effect, and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of the Pangenotypic Anti-Hepatitis C Virus Drug Holybuvir in Healthy Chinese Subjects.Antimicrob Agents Chemother. 2023 Mar 16;67(3):e0129522. doi: 10.1128/aac.01295-22. Epub 2023 Feb 21. Antimicrob Agents Chemother. 2023. PMID: 36809048 Free PMC article.
References
-
- Lok AS. Prevention of hepatitis B virus-related hepatocellular carcinoma. Gastroenterology. 2004;127:S303–S309. - PubMed
-
- Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China. J Gastroenterol Hepatol. 2013;28(Suppl 1):7–10. - PubMed
-
- Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol. 2013;59:160–168. - PubMed
-
- Fan JG. Epidemiology of alcoholic and nonalcoholic fatty liver disease in China. J Gastroenterol Hepatol. 2013;28(Suppl 1):11–17. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous